July 12, 2022 -- Bio-Rad Laboratories has extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to brentuximab vedotin (Adcetris), secukinumab (Cosentyx), and the secukinumab-interleukin 17A (IL-17A) drug-target complex.
Brentuximab vedotin is an antibody drug conjugate used to treat Hodgkin lymphoma, and secukinumab is used to inhibit a patient's inflammatory response in several diseases, including ankylosing spondylitis, psoriasis, and psoriatic arthritis. Bio-Rad's new, highly specific antibodies can be used in the bioanalysis and drug monitoring of brentuximab vedotin, secukinumab, as well as their biosimilars.
The antibrentuximab vedotin and antisecukinumab antibodies are approved for in vitro research purposes, for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and for patient monitoring.
Copyright © 2022 scienceboard.net